A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intens
ECMO is widely used in patients with refractory respiratory and/or circulatory failure.The data shows that the incidence of bleeding and thrombotic events is still above 40%,and it is closely related to the increase in mortality rate.Therefore, optimizing ECMO anticoagulation management to reduce bleeding and thromboti
| Condition(s) | ECMO |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | ECMO is widely used in patients with refractory respiratory and/or circulatory failure.The data shows that the incidence of bleeding and thrombotic events is still above 40%,and it is closely related to the increase in mortality rate.Therefore, optimizing ECMO anticoagulation management to reduce bleeding and thrombotic events is a key scientific issue that urgently needs to be addressed. |
| Who can participate | Inclusion Criteria: * age older than 18 years old * received ECMO because of severe respiratory failure Exclusion Criteria: * anticoagulant contraindications * cerebral infarction or suspected patients * severe hypertension * women in gestational and lactational period * hemophilia * allergic to heparin or Nafamostat * unwilling or unable to complete the study |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Beijing Chao Yang Hospital |
| Locations | Beijing, Beijing Municipality, China |
| Start date | 2024-11-01 |
| NCT ID | NCT06676085 |
| Official listing | https://clinicaltrials.gov/study/NCT06676085 |